# A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

> **NCT03907202** · PHASE1 · TERMINATED · sponsor: **KeyBioscience AG** · enrollment: 25 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** Daily injection of KBP/placebo for up to 28 days

## Key facts

- **NCT ID:** NCT03907202
- **Lead sponsor:** KeyBioscience AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-17
- **Primary completion:** 2019-12-03
- **Final completion:** 2019-12-03
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The trial was planned to be conducted in 4 cohorts but was terminated after completion of Cohort 2 for strategic reasons due to limited PD effects.
- **Last updated:** 2020-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03907202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03907202, "A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03907202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*